Til transaksjoner
Helse & omsorg

Shield Therapeutics has completed a fundraising

Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.

Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.

TRANSAKSJONSTYPE
Parter

Kontakt ansvarlige rådgivere

 Geoff  Nash

Geoff Nash

Director
London, Storbritannia
Oaklins Cavendish

Relaterte transaksjoner

Xeros Technology Group has completed a placing, subscription and retail offer
Maskiner og komponenter

Xeros Technology Group has completed a placing, subscription and retail offer

Xeros Technology Group plc has raised funds to drive forward its commercialization strategy.

Les mer
PCI Pal has completed an equity raise
Finansielle tjenester | TMT

PCI Pal has completed an equity raise

PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.

Les mer
CARSO Group has acquired a majority stake in AQCF Group
Private equity | Tjenesteytende virksomheter | Helse & omsorg

CARSO Group has acquired a majority stake in AQCF Group

CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.

Les mer